Alzamend Neuro, Inc.
ALZN • NASDAQ
Alzamend Neuro, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Stephan Jackman, with a market cap of $4.0M.
CEOStephan Jackman
Next Earnings
No upcoming earnings scheduled for Alzamend Neuro, Inc.
No earnings announcement scheduled
Earnings History
Past 12 earnings reports for Alzamend Neuro, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Q3 2026 | -$0.58Est: -$1.45 | +60.0% | - | — |  10-Q |
| Dec 9, 2025 | Q2 2026 | -$0.30Est: -$1.51 | +80.1% | - | — | 10-Q |
| Sep 10, 2025 | Q1 2026 | -$1.28Est: -$1.89 | +32.3% | - | — | 10-Q |
| Mar 10, 2025 | Q3 2025 | -$0.19Est: -$0.77 | +75.3% | - | — | 10-Q |
| Dec 12, 2024 | Q2 2025 | -$0.40Est: -$0.38 | -5.3% | - | — | 10-Q |
| Sep 11, 2024 | Q1 2025 | -$1.25Est: -$2.38 | +47.5% | - | — | 10-Q |
| Jul 30, 2024 | Q4 2024 | -$1.20Est: -$2.70 | +55.6% | - | — | 10-K |
| Mar 25, 2024 | Q3 2024 | -$3.80Est: -$3.20 | -18.7% | - | — | 10-Q |
| Dec 15, 2023 | Q2 2024 | -$4.40 | — | - | — | — |
| Sep 13, 2023 | Q1 2024 | -$6.00Est: -$7.50 | +20.0% | - | — | 10-Q |
| Jul 27, 2023 | Q4 2023 | -$4.50Est: -$6.00 | +25.0% | - | — | — |
| Mar 16, 2023 | Q3 2023 | -$9.00Est: -$6.00 | -50.0% | - | — | — |